During the past two decades, much interest has focused on the pathogenic role of autoreactive T-cells recognizing myelin in both multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE). The vast majority of data support the hypothesis that EAE and, by analogy, multiple sclerosis are diseases mediated by autoreactive Th1 T-cells, much as rheumatoid arthritis, autoimmune diabetes, psoriasis or in¯ammatory bowel disease. Thus, much effort has been put into developing multiple sclerosis therapies that eliminate more or less speci®cally autoimmune T-cells or shift the balance from the presumed pathogenic Th1 to the presumed bene®cial Th2 phenotype of T-cells (Noseworthy et al., 2000) . The two currently approved disease modifying treatments, IFN-b and glatiramer acetate (GA), are thought to exert their bene®cial effect in multiple sclerosis at least in part by this mechanism of action.
But clinical observations mainly related to the`clinical± radiological paradoxon' indicate that suppression of a deviated immune response may be an inappropriately simplistic approach: (i) multiple sclerosis in¯ammatory lesions, as depicted with high sensitivity by contrast enhanced magnetic resonance imaging (MRI), did not predict later changes in impairment or disability (Kappos et al., 1999) ; (ii) in primary progressive and also late secondary progressive multiple sclerosis, the disease courses most closely associated with increasing disability, less in¯ammatory changes are observed than in relapsing±remitting disease; and (iii) currently available immunomodulatory and immunosuppressive treatments of multiple sclerosis have a much more pronounced effect on in¯ammatory activity (as shown by serial MRI) than on clinical disease.
Recently, an increasing body of experimental evidence supports the hypothesis of a`dual role' of the immune system in demyelinating disease, emphasizing potentially bene®cial effects of in¯ammation. In a series of experiments it was elegantly shown that in models of crush injury of the optic nerve or contusion of the spinal cord in rats, activated T-cells speci®c for CNS antigens, e.g. basic myelin protein, but not against non-CNS antigens, protect the injured nervous system tissue from secondary degeneration and promote repair (Moalem et al., 1999 (Moalem et al., , 2000 Cohen and Schwartz, 1999; Yoles et al., 2001) . This neuroprotective effect of autoimmune T-cells is at least partly mediated by the release of neurotrophic factors (Hohlfeld et al., 2000) . Activated human T-cells but also B-cells and macrophages produce neurotrophic factors (Kerschensteiner et al., 1999; Besser and Wank, 1999) . Extending the ®rst observations by Kerschensteiner et al. (1999) , detailed immunohistochemical analysis (Stadelmann et al., 2002) has shown that brainderived neurotrophic factor (BDNF) and its receptor trkB are present in multiple sclerosis lesions thus suggesting a role for this neurotrophin in multiple sclerosis.
These ®ndings would have major therapeutic implications if it were possible to obtain T-cells which react with CNS antigens and exert such protective effects without the destructive potential of CNS autoimmunity. GA should be a logical candidate for the induction of such cells, as it is nonpathogenic, capable of inducing a protective immune response in EAE and partially bene®cial in relapsing± remitting multiple sclerosis.
In this issue of Brain, Ziemssen et al. (2002) provide ®rm evidence that indeed BDNF is secreted by GAA reactive human T-cell lines in vitro. Interestingly, the four T-cell lines described secreted roughly equal amounts of BDNF although they were of stable Th0, Th1, Th2 or combined Th1/Th0 phenotypes, usually known for very diverging patterns of cytokine secretion. They hypothesize that treatment with GA in multiple sclerosis may not only exert an anti-in¯ammatory effect by a shift from secretion of Th1 to Th2 cytokines (Duda et al., 2000; Neuhaus et al., 2000) but in addition mediate neuroprotection by the secretion of BDNF.
These data are in line with earlier results from Kipnis et al. (2000) who found high secretion of BDNF and moderate secretion of NT3, NT4/5 and NGF in both passively transferred and actively induced GA reactive rat T-cells that were capable of mediating neuroprotection in an optic nerve crush injury model.
Although encouraging, these ®ndings provide only indirect evidence of GA-speci®c T-cell induced neuroprotection in the human disease multiple sclerosis. It is not clear if and in what quantities GA-speci®c T-cells reach the CNS of multiple sclerosis patients and ifÐonce thereÐthese cells produce suf®cient quantities of BDNF and perhaps other neurotrophins.
Recent neuroimaging ®ndings in patients treated with GA seem to further support an anti-degenerative role of GA in
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The Janus face of CNS-directed autoimmune response: a therapeutic challenge ã Guarantors of Brain 2002 Brain (2002 , 125, 2379±2380 multiple sclerosis: in addition to a signi®cant reduction of in¯ammatory activity (which was less pronounced than in similar studies with interferon-b) treatment with GA also resulted in a decrease of the proportion of new lesions that evolved into T1 hypointense lesions, a lesion type more indicative of tissue destruction (Filippi et al., 2001) . This ®nding as well as similar observations in the long term follow up of the original patient cohort of the pivotal GA trial are still controversial and derived from secondary (post hoc) analysis and certainly need con®rmation in prospective studies.
More research is needed to elucidate the roles of immune cells in neuroprotection and repair mechanisms in the CNS, if we ultimately want to explore the Janus shape of autoimmune myelin reactive T-cells in CNS diseases for the development of future therapeutics.
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